Please use this identifier to cite or link to this item: https://doi.org/10.1016/S0022-5347(01)67113-1
DC FieldValue
dc.titleInterleukin-6 production by bladder tumors is upregulated by BCG immunotherapy
dc.contributor.authorEsuvaranathan, K.
dc.contributor.authorAlexandroff, A.B.
dc.contributor.authorMcIntyre, M.
dc.contributor.authorJackson, A.M.
dc.contributor.authorPrescott, S.
dc.contributor.authorChisholm, G.D.
dc.contributor.authorJames, K.
dc.date.accessioned2011-11-30T06:21:03Z
dc.date.available2011-11-30T06:21:03Z
dc.date.issued1995
dc.identifier.citationEsuvaranathan, K., Alexandroff, A.B., McIntyre, M., Jackson, A.M., Prescott, S., Chisholm, G.D., James, K. (1995). Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. Journal of Urology 154 (2 I) : 572-575. ScholarBank@NUS Repository. https://doi.org/10.1016/S0022-5347(01)67113-1
dc.identifier.issn00225347
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/29280
dc.description.abstractPurpose: To determine whether BCG therapy could upregulate interleukin-6 (IL-6) production in human transitional cell carcinomas (TCC). Materials and Methods: Immunohistochemistry of tumor biopsies and urinary cytospins and ELISA studies of urine from bladder cancer patients and TCC cell-line supernatants, before and after exposure to BCG, were performed. Results: Constitutive staining for IL-6 was found in the majority of bladder tumors. Interleukin-6 was detected in the urine of all 13 patients with carcinoma in situ and increased 5-fold during BCG therapy. Levels were variable but were greater in nonresponders (p <0.01). During therapy both detached bladder urothelial cells and polymorphonuclear leukocytes stained for IL-6. Production of IL-6 increased in only 3 cell lines after exposure to BCG, but all 7 cell lines showed increases after exposure to interferon-γ (p =0.015). Grade 3 cell lines showed much greater upregulation than grade 1 and 2 cell lines. Conclusions: The increase in IL-6 during BCG therapy may be caused by urothelial cells as well as leukocytes. The higher levels seen in nonresponders may be due to either higher grade or persisting tumor.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/S0022-5347(01)67113-1
dc.sourceScopus
dc.subjectBCG vaccine
dc.subjectbladder neoplasms
dc.subjectinterferon type II
dc.subjectinterleukin-6
dc.typeArticle
dc.contributor.departmentSURGERY
dc.description.doi10.1016/S0022-5347(01)67113-1
dc.description.sourcetitleJournal of Urology
dc.description.volume154
dc.description.issue2 I
dc.description.page572-575
dc.description.codenJOURA
dc.identifier.isiutA1995RJ05000070
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

54
checked on Oct 22, 2021

WEB OF SCIENCETM
Citations

58
checked on Oct 22, 2021

Page view(s)

188
checked on Oct 14, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.